Kymera Therapeutics Inc

Common Name

Kymera Therapeutics

Country

United States

Sector

Healthcare

Industry

Biotechnology

Employees

218

Ticker

KYMR

Exchange

NASDAQ/NMS

Website

www.kymeratx.com

Description

Kymera Therapeutics Inc. is a pioneering biotechnology company focused on the development of targeted protein degradation therapies. These therapies are aimed at disease-causing proteins that have tra... Show more

Financial Statements of Kymera Therapeutics

Below are the financial statements of Kymera Therapeutics, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.

Income Statement (as reported) Balance Sheet (as reported)

All figures in thousands of USD	2024	2023
Current assets	—	—
Cash and cash equivalents	120,256^a	109,966^a
Marketable securities	368,488^a	264,915^a
Accounts receivable	0^a	15,000^a
Contract assets	947^a	3,762^a
Prepaid expenses and other current assets	20,577^a	11,674^a
Total current assets	510,268^a	405,317^a
Assets	—	—
Marketable securities, non-current	362,159^a	61,434^a
Property and equipment, net	50,457^a	48,134^a
Right-of-use assets, operating leases	47,407^a	52,945^a
Other non-current assets	1,950^a	2,118^a
Restricted cash	5,794^a	5,811^a
Total assets	978,035^a	575,759^a
Current liabilities	—	—
Accounts payable	5,989^a	7,075^a
Accrued expenses	34,867^a	33,864^a
Deferred revenue	13,576^a	37,883^a
Operating lease liabilities	11,594^a	5,068^a
Finance lease liabilities	1,518^a	1,277^a
Other current liabilities	223^a	524^a
Total current liabilities	67,767^a	85,691^a
Non-current liabilities	—	—
Deferred revenue, net of current portion	0^a	16,768^a
Operating lease liabilities, net of current portion	72,423^a	77,028^a
Finance lease liabilities, net of current portion	2,226^a	1,301^a
Other non-current liabilities	0^a	0^a
Liabilities and stockholders’ equity	—	—
Total liabilities	142,416^a	180,788^a
Stockholders’ equity	—	—
Common stock	7^a	6^a
Additional paid-in capital	1,591,707^a	926,269^a
Accumulated deficit	-754,610^a	-530,752^a
Accumulated other comprehensive loss	-1,485^a	-552^a
Total stockholders’ equity	835,619^a	394,971^a
Total liabilities and stockholders’ equity	978,035^a	575,759^a

Verified Sources Behind Kymera Therapeutics’s Financial Fundamentals Data

Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Kymera Therapeutics’s data sources below and access millions more through our Disclosure Search.

a. Kymera Therapeutics's 10-K 2024

Trace every data point back to Kymera Therapeutics’s disclosures

Sign up for Tracenable and access millions of corporate disclosures, including annual reports and sustainability filings from global companies, completely free of charge.

Real-Time & Standardized Financials

Access Standardized Financial Statements within Minutes of Disclosure

At Tracenable, we're exploring the launch of real-time standardized financial datafeeds and APIs covering global equities. Unlike limited and inconsistent XBRL parsing, our approach aims to deliver clean, comparable, and fully traceable data seconds after publication.

Could this solution support your investment or analytical workflows?

Explore Peer Companies

Welcome Back to Tracenable

Sign in to your account

Kymera Therapeutics Inc

Financial Statements of Kymera Therapeutics

Verified Sources Behind Kymera Therapeutics’s Financial Fundamentals Data

Access Standardized Financial Statements within Minutes of Disclosure

Explore Peer Companies

Arcellx Inc

Vericel Corp

Blueprint Medicines Corp

Immunovant Inc

Ultragenyx Pharmaceutical Inc

Cytokinetics Inc